The Association Between Type 2 Diabetes and Bone Microarchitecture Assessed by HR-pQCT

Area of Science:

• Bone Metabolism and Endocrinology
• Metabolic Disorders and Bone Health
• Medical Imaging and Biomechanics

Background:

• Type 2 diabetes (T2DM) is linked to higher bone mineral density (BMD) but increased fracture risk.
• Understanding bone microarchitecture in T2DM is crucial for explaining bone fragility.
• Existing research shows complex relationships between T2DM, bone density, and fracture outcomes.

Purpose of the Study:

• To investigate differences in bone microarchitecture between T2DM patients and controls.
• To explore the impact of glucose-lowering treatments, particularly metformin, on bone structure.
• To elucidate the mechanisms behind increased fracture risk in T2DM despite potentially higher BMD.

Main Methods:

• Cross-sectional matched analysis of 159 T2DM patients and 318 controls from three prospective cohorts.
• High-resolution peripheral quantitative computed tomography (HR-pQCT) used to assess cortical and trabecular bone microarchitecture.
• Subgroup analyses compared bone parameters based on glucose-lowering treatments (metformin vs. non-metformin oral agents, metformin vs. insulin).

Main Results:

• T2DM patients exhibited modest, heterogeneous, and site/sex-specific differences in bone microarchitecture compared to controls.
• Men with T2DM had higher femoral neck aBMD; both sexes showed reduced bone size at tibia/radius.
• Metformin use was associated with improved cortical microarchitecture (lower porosity, greater thickness/area) and higher hip T-scores compared to other oral therapies.

Conclusions:

• Bone microarchitecture alterations in T2DM are subtle and vary by skeletal site and sex.
• Metformin may confer a more favorable cortical bone profile in T2DM patients.
• Further research is needed to confirm these findings and understand their clinical implications for fracture risk.